Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Banner

Reuters Global Pharma Awards – Finalist

March 7th 2022September 13th 2021

Read More

Logo

Shorla Oncology Announces Partnership with EVERSANA

March 7th 2022August 17th 2021

Read More

Photo

Shorla Oncology Expands into the U.S.

March 7th 2022July 14th 2021

Read More

Shorla Oncology

Team Shorla Oncology complete 100k in 30 days for Breast Cancer

March 7th 2022June 30th 2021

Read More

Shorla Oncology

FDA filing acceptance and priority review received for SH-111

March 7th 2022April 23rd 2021

Read More

Logo

United Conference of Generics, Vaccines and Biosimilars

May 14th 2021April 9th 2021

Read More

Logo

30 % Club Ireland

March 7th 2022March 24th 2021

Read More

Photo

Shorla Oncology Announces Chief Commercial Officer

March 7th 2022March 2nd 2021

Read More

Photo

Shorla Oncology – Q&A with Tracy Woody

March 7th 2022February 25th 2021

Read More

Older posts
Newer posts
Page1 … Page8 Page9 Page10 … Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.